Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Pericardial effusion - cave lymphosarcoma
Gina.jpg Foto: Dr. Stefanie Peters
Pericardial effusion (PE) is in the list of differential diagnoses when a patient presents with weakness or collapse, weak pulses and muffled heart sounds. Many differentials must be considered, but this recently published study shows that one should never forget to put cardiac or pericardial lymphosarcoma on the list of differentials...

The clinician may elect to perform radiographs, which reveal a globoid cardiac silhouette, followed by an ultrasound examination defining the fluid within the pericardial cavity.

At this point, some of the common diagnoses, including hemangiosarcoma with hemorrhage, idiopathic and infectious pericarditis, quickly come to mind. However, recently investigators from Tufts and the University of Wisconsin-Madison reported on a series of cases in dogs where the cause of the PE was lymphosarcoma (MacGregor et al in the Proceedings of the 21st ACVIM Forum, 2003, pg 952). Of course, the definitive long-term treatment of lymphosarcoma is markedly different than the more commonly considered causes of PE.

These nine cases all presented with signs relating to their pericardial disease. They had collapse episodes, and most had ascites. Blood tests were not helpful in reaching the diagnosis. Following the imaging by radiographs and ultrasound, pericardiocentesis and cytological analysis revealed the presence of neoplastic lymphocytes.

Three of the patients were treated with combination chemotherapies which included doxorubicin, resulting in survivals of 157, >328, and >659 days, respectively. Survival times are comparable with multicentric lymphosarcoma if cardiac issues can be successfully managed.

Thus, the clinician should be aware that pericardial effusion may be the only presenting sign of cardiac or pericardial lymphosarcoma.

In humans it is noted that sometimes biopsy of the heart or pericardium may be necessary when cytology does not provide a conclusive diagnosis (Gowda et al in Angiology 599-604 Sept.-Oct. 2003). One should consider this option in refractory PE of uncertain etiology in our veterinary patients.

A pericardial window may be opened by thoracotomy if necessary to improve cardiovascular hemodynamics (Stepian et al J Small Animal Practice 2000, pgs 342-347). Alternatively, the biopsy may be obtained and window opened via a videothoracoscopic procedure (Kovak et al, JAVMA 2002, Volume 221, No. 7).

Source: Ronald Lyman (2004): Pericardial lymphosarcoma associated with pericardial effusion. In: DVM Newsmagazine April 1, 2004







Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

JAK 1/2 inhibitor in the treatment of canine B-cell lymphomamembers
Canine diffuse large B-cell lymphoma (DLBCL) is a common and aggressive hematologic malignancy. The lack of conventional therapies with sustainable efficacy warrants further investigation of novel therapeutics. The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathways play important roles in the pathogenesis of hematologic malignancies in humans including DLBCLs. AZD1480 and CYT387 are novel JAK1/2 inhibitors that have been used in clinical trials for treating various hematologic cancers in humans. No studies have characterized the antitumor effects of JAK inhibitors on DLBCL in dogs. Do they react like humans?

  • Gastric pH and Serum Gastrin Concentrations in Cats with Chronic Kidney Diseasemembers
  • Topical ophthalmic 1% atropine and heart rate and rhythm in normal dogsmembers
  • Crystalloid Solutions and the Acid-Base Balance in Domestic Animalsmembers
  • Punctate retinal hemorrhage in dogsmembers
  • Classification system for cleft lip and palate in dogsmembers
  • Atypical hemolymphoid neoplasia causing aberrant CD3 expression in a dogmembers
  • Cell-Free DNA and DNase Activity in Dogs with IMHAmembers
  • Chronic Diarrhea in Dogs members
  • Safety of a benazepril and pimobendan combination tablet in healthy dogsmembers
  • Tear fluid collection with ophthalmic sponges in dogs and catsmembers
  • Metabolic and cardiac variables in dogs with obesitymembers
  • Vertebral heart size in chinchillas members


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved